The FDA accepts Immunomedics’ (NASDAQ:IMMU) Biologics License Application (BLA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease, as a complete class 2 response.
The PDUFA target action date of the resubmitted BLA is June 2, 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.